{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:36:26Z","timestamp":1792172186526,"version":"4.4.0"},"reference-count":10,"publisher":"S. Karger AG","issue":"5-6","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology"],"published-print":{"date-parts":[[2013]]},"abstract":"<jats:p>The aim of the present study was to assess the anticancer effect of several naftopidil analogues on human malignant mesothelioma cell lines NCI-H28, NCI-H2052, NCI-H2452, and MSTO-211H, human lung cancer cell lines A549, SBC-3, and Lu-65, human hepatoma cell lines HepG2 and HuH-7, human gastric cancer cell lines MKN-28 and MKN-45, and human bladder cancer cell lines 253J, 5637, KK-47, TCCSUP, T24, and UM-UC-3, human prostate cancer cell lines DU145, LNCap, and PC-3, and human renal cancer cell lines ACHN, RCC4-VHL, and 786-O. We newly synthesized 21 naftopidil analogues, and of them 1-[2-(2-methoxyphenylamino)ethylamino]-3-(naphthalene-1-yloxy)propan-2-ol (HUHS1015) most efficiently reduced cell viability for all the investigated malignant mesothelioma cell lines in a concentration (1-100 \u03bcmol\/l)-dependent manner. HUHS1015 reduced cell viability for all other investigated cancer cell lines, to an extent similar to that for malignant mesothelioma cell lines. HUHS1015 activated caspase-3 and -4, without activating caspase-8 and -9, in malignant mesothelioma cell lines. The results of the present study, thus, indicate that HUHS1015 induces apoptosis in a variety of cancer cells, possibly by activating caspase-4 and the effector caspase-3.<\/jats:p>","DOI":"10.1159\/000351747","type":"journal-article","created":{"date-parts":[[2013,6,28]],"date-time":"2013-06-28T07:04:52Z","timestamp":1372403092000},"page":"339-345","source":"Crossref","is-referenced-by-count":15,"title":["1-[2-(2-Methoxyphenylamino)ethylamino]-3-(naphthalene-1-yloxy)propan-2-ol as a Potential Anticancer Drug"],"prefix":"10.1159","volume":"91","author":[{"given":"Takeshi","family":"Kanno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Nishizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2013,6,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1254%2Fjjp.79.447"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1158%2F1940-6207.CAPR-10-0189"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002%2Fijc.23095"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1159%2F000342797"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007%2FPL00004999"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016%2FS0014-2999%2899%2900222-8"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159%2F000339048"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1083%2Fjcb.200310015"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093%2Fhmg%2Fddl105"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.bbrc.2009.10.141"}],"container-title":["Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/351747","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/351747","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:29:48Z","timestamp":1745432988000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000351747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":10,"journal-issue":{"issue":"5-6","published-online":{"date-parts":[[2013,7,1]]},"published-print":{"date-parts":[[2013,7,19]]}},"URL":"https:\/\/doi.org\/10.1159\/000351747","archive":["Portico"],"relation":{},"ISSN":["0031-7012","1423-0313"],"issn-type":[{"value":"0031-7012","type":"print"},{"value":"1423-0313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}